BioBoost
The MLSC is actively evaluating the development of a BioBoost program intended to support companies creating or expanding biomanufacturing or medtech advanced manufacturing presence in Massachusetts.
The MLSC BioBoost program is in stage one, seeking input from our stakeholders.
Massachusetts is a global leader in life science research and development, but the Commonwealth also has a strong and growing manufacturing presence. Many of the world’s top biotech, pharma, and medtech companies have chosen to co-locate their R&D and manufacturing operations in Massachusetts to take advantage of the density of talent, collaborative spirit, and opportunities for consistent iteration between the lab and production teams. These close collaborative connections work even better on the cutting edge, when the manufacturing processes must be the most nimble, creative, and responsive to the lightning speed of science.
The MLSC is seeking to create a BioBoost Manufacturing Scale-Up program to support companies creating or expanding biomanufacturing or medtech advanced manufacturing presence in Massachusetts, as well as real estate developers who may be seeking to develop additional GMP space.
The survey link below seeks feedback from stakeholders including companies that already manufacture in MA, those who may be considering the possibility, whether in the short or long term, real estate developers, property owners, incubators/accelerators, and companies or nonprofits meeting adjacent ecosystem needs such as service providers or workforce development organizations. From the information we collect, we will aim to launch a responsive and adaptive competitive program to fund capital investments—such as buildout, renovation, or equipment needs—to create a funding tool that best meets current and future industry needs to support increased manufacturing activity in Massachusetts.
Your input on this survey is immensely valuable and appreciated.
Please note this survey is not a mechanism to pre-qualify any individual or organization for future funding from MLSC, and is not intended to guarantee the MLSC will offer funding opportunities as a result of the outcomes of the survey.
Olaris is a precision diagnostics company that is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging their CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, they are able to harness the power of the body’s own communication system to discover and develop their pipeline of myOLARIS precision diagnostics.